PACS: Highlights from the RBC Healthcare Conference

Research evidence excerpt

PACS: Highlights from the RBC Healthcare Conference

ort systems are now better prepared to absorb larger and more complex transactions than at any

prior point in the company's history. M&A was removed from guidance not as a signal of reduced activity but for transparency

purposes, as prior nominal inclusion created confusion about the underlying organic portfolio trajectory. Management was explicit

that the pipeline supports potentially larger, chunkier deals going forward, and that the decision to go public was in part motivated

by the desire to access institutional capital to fund exactly this kind of scaled growth.

On managed care, management pushed back on the broader industry narrative around heightened clinical review activity,

noting that payer scrutiny of care necessity is not a new dynamic and that PACS has not observed any incremental review

pressure. On the contrary, the company described an increase in managed care contract negotiations and renegotiations over the

past 12 to 18 months, with plans seeking density, bed access, and quality operators in key markets. Managed care as a percentage

of skilled census increased in 1Q relative to any quarter of the prior year, which management views as a direct reflection of

its clinical reputation and outcomes performance across metrics such as length of stay and return-to-acute rates. The clinical

investment thesis is central to the PACS model, with management describing a deliberate progression where deploying uniform

clinical systems, investing in physical plant and equipment, and training staff to handle higher-acuity patients gradually expands

the range of patients the facility can serve, making it the preferred destination for both providers and payers seeking a low-cost,

high-quality post-acute setting.